Company news

Neuphoria Therapeutics Inc. news in 2025

Neuphoria Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

December 8, 2025

Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium

December 4, 2025

Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

December 2, 2025

Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions

December 1, 2025

Neuphoria Therapeutics Inc. Sends Letter to Stockholders

November 24, 2025

Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value

November 11, 2025

Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process

October 27, 2025

Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder

October 20, 2025

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

September 29, 2025

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

September 4, 2025

Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

August 28, 2025

Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting

May 27, 2025

Neuphoria Provides First Quarter 2025 Business Updates

May 20, 2025

Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

April 15, 2025

Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025

March 3, 2025

Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck

February 11, 2025

Decks in 2025